Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stock Report

Market Cap: US$8.3m

Cyclerion Therapeutics Past Earnings Performance

Past criteria checks 0/6

Cyclerion Therapeutics has been growing earnings at an average annual rate of 49.4%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 50.2% per year.

Key information

49.4%

Earnings growth rate

57.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-50.2%
Return on equity-64.4%
Net Margin-2,722.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

Revenue & Expenses Breakdown

How Cyclerion Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CYCN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-56-1
30 Jun 240-1070
31 Mar 240-1170
31 Dec 230-1380
30 Sep 230-15101
30 Jun 23-13100
31 Mar 230-8120
31 Dec 220-18130
30 Sep 221-25140
30 Jun 222-48160
31 Mar 225-51190
31 Dec 214-52210
30 Sep 214-60230
30 Jun 214-68270
31 Mar 211-71270
31 Dec 202-78290
30 Sep 204-85320
30 Jun 205-93280
31 Mar 206-106340
31 Dec 195-123340
30 Sep 193-128320
30 Jun 192-130360
31 Mar 190-12731-22
31 Dec 180-115280
30 Sep 180-1122224
30 Jun 180-1081945
31 Mar 180-991584
31 Dec 170-941579

Quality Earnings: CYCN is currently unprofitable.

Growing Profit Margin: CYCN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 49.4% per year.

Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CYCN has a negative Return on Equity (-64.42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclerion Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Martin AusterCredit Suisse
Joon So LeeTruist Securities